Navigation Links
Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
Date:2/4/2009

ANDOVER, Mass., Feb. 4 /PRNewswire/ -- Genesis HealthCare, a provider of long-term care services in New England for more than 25 years, announced today that Wendy LaBate has been promoted to Senior Vice President of Operations for the Northeast Area. In her new position, LaBate will be responsible for providing day-to-day oversight and support to all of Genesis' Regional Vice Presidents of Operations and Administrators in six states in order to support center operations, improve efficiencies and promote patient-centered care. In addition, LaBate represents Genesis and its services to local legislators, regulators and community associations throughout New England.

Ms. LaBate has been employed by Genesis HealthCare for more than fifteen years, most recently as Vice President of Clinical Operations for the Northeast Area. In that capacity, LaBate had oversight for the nursing care delivery systems and outcomes for all the Genesis skilled nursing and assisted living facilities in six New England states. In her prior work for Genesis, she has also served as an Administrator, Director of Nurses, and a Quality Improvement Coordinator at several Genesis centers in Massachusetts.

"We are thrilled to promote Wendy to the position of Senior Vice President of Operations," says Richard Blinn, President of Genesis HealthCare's Northeast Area. "Wendy is a seasoned healthcare executive, with more than 25 years experience in the healthcare industry. Her clinical expertise and leadership are strong assets to our Northeast Area and the entire Company."

Ms. LaBate earned both a Bachelor's degree and a Master's degree in nursing from the University of Phoenix. In addition, she holds a Master's in Healthcare Administration from the University of Massachusetts and a Bachelor's degree in Healthcare Administration from Rivier College. She has a Diploma in Nursing from Lowell General Hosp
'/>"/>

SOURCE Genesis HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
2. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
3. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
4. OmegaGenesis Announces Angiogenesis Application Collaboration
5. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
6. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
7. Cardiogenesis Reports Third Quarter 2008 Results
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Genesis Pharmaceuticals Launches New Corporate Website
10. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
11. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of value, aluminium ... production volume reached close to 1.84 million tonnes in the same year. As ... of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide production posted ...
(Date:7/28/2015)... , ... July 28, 2015 , ... VetStem Biopharma will ... stem cell credentialing course to local area veterinarians. , The tour and course will ... units at no charge) at VetStem’s Poway facility. Staff members are welcome to attend ...
(Date:7/28/2015)...  Kerastem Technologies announce that the Company has received ... For Biologics Evaluation and Research (CBER) Office of Cellular, ... investigating the safety and feasibility of the Company,s technology ... baldness (androgenic alopecia). The phase II study, ... in Europe and ...
(Date:7/28/2015)... 2015 CSL Behring announced today ... for review the company,s Biologics License Application (BLA) for ... the treatment of hemophilia A. In the pivotal clinical ... Hemophilia A is a congenital bleeding disorder ... affected patients are male. People with hemophilia A may ...
Breaking Biology Technology:EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... HIFU Revenue ... FY2007 Annual Targets Under Review, BEIJING, ... (Nasdaq: CMED ), a leading China-based,medical device company ... and high intensity focused ultrasound tumor,therapy system, today announced ...
... LAKE CITY, Aug. 27 ARUP Laboratories, a ... leader in,innovative laboratory research and development, announced today ... with Premier Purchasing,Partners, L.P., one of the nation,s ... systems. The agreement extends a previous,contract between ARUP ...
... IDM Pharma (Nasdaq:,IDMI) today announced that Jeffrey W. ... Medical Officer and Senior Vice President,of Research and Development. ... report to President and CEO Timothy P. Walbert. ... experience to,IDM Pharma and will lead the regulatory and ...
Cached Biology Technology:China Medical Technologies Reports First Quarter Financial Results 2China Medical Technologies Reports First Quarter Financial Results 3China Medical Technologies Reports First Quarter Financial Results 4China Medical Technologies Reports First Quarter Financial Results 5China Medical Technologies Reports First Quarter Financial Results 6China Medical Technologies Reports First Quarter Financial Results 7China Medical Technologies Reports First Quarter Financial Results 8China Medical Technologies Reports First Quarter Financial Results 9China Medical Technologies Reports First Quarter Financial Results 10China Medical Technologies Reports First Quarter Financial Results 11China Medical Technologies Reports First Quarter Financial Results 12China Medical Technologies Reports First Quarter Financial Results 13China Medical Technologies Reports First Quarter Financial Results 14ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 2IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 3IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 4IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development 5
(Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... have found that a type of amoeba acts as ... found in healthcare environments this discovery has implications for ... single cell amoeba, Acanthamoeba polyphagam commonly eats and digests ... However, instead of being digested by the amoeba, MRSA ...
... (HSP) can be utilized as a vaccine to ... National University (South Korea) today presented the findings ... bacterium Porphyromonas gingivalis heat-shock protein (HSP) 60 as ... bone loss.Recombinant P. gingivalis HSP60 was produced and ...
... of Utah researchers have taken a potentially powerful new ... illnesses out of the test tube and into animals ... in mice. , The research has particularly important implications ... disease that damages both nerves and blood vessels. , ...
Cached Biology News:Proteins spur diabetic mice models to grow blood vessels, nerves 2
Vitellogenin (Japanese medaka) Standard...
nuclear RNA export factor 1, mRNA...
... of gene expression) technology allows ... profiles generated by SAGE are ... transcripts making it possible to ... Kit is designed to make ...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: